期刊
FRONTIERS IN PSYCHIATRY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fpsyt.2018.00271
关键词
schizophrenia; galectin-3; interleukin-33; metabolic syndrome; cardiovascular issues
类别
资金
- Ministry of Science and Technological Development of Republic of Serbia [175103, 175069]
- Faculty of Medical Sciences, University of Kragujevac [JP 12-09, JP 15-05]
Schizophrenia and treatment of this disorder are often accompanied with metabolic syndrome and cardiovascular issues. Alterations in the serum level of innate immune mediators, such as interleukin-33 (IL-33) and its receptor IL-33R (ST2) and Galectin-3 (Gal-3) were observed in these conditions. Moreover, these parameters are potential prognostic and therapeutic markers. There is also accumulating evidence that these molecules play a role in neuroinflammation. Therefore, in this study we have investigated the serum level of Gal-3, IL-33 and soluble ST2 (sST2) in different stages of schizophrenia. Gal-3 levels were elevated in remission and lower in schizophrenia exacerbation in comparison with controls. Levels of IL-33 and sST2 are higher in schizophrenia exacerbation in comparison with controls and patients in remission. This initial analysis of new markers of neuroinflammation suggested their involvement in schizophrenia pathophysiology and/or cardiometabolic comorbidity. HIGHLIGHTS - Gal-3 serum levels are elevated in remission and lower in schizophrenia exacerbation. - IL-33 and sST2 serum levels are higher in schizophrenia exacerbation. - sST2 serum levels negatively correlate with N subscore in acute psychosis. - sST2 serum levels negatively correlate with cholesterol in relapse and positively with CK-MB in schizophrenia remission
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据